Exclusive Content
Biotech & Life Sciences in China Update: China Expands Patent Linkage to Biologics — Key Takeaways
Biotech & Life Sciences in China Update: China Expands Patent Linkage to Biologics — Key Takeaways On April 15, 2025, the China National Drug Administ
Biotech & Life Sciences in China Update: CDE Launches Fast-Track IND Pilot for Gene Therapies — Key Takeaways
CDE Launches Fast-Track IND Pilot for Gene Therapies in China — Key Takeaways for Foreign Biotechs On April 1, 2025, the Center for Drug Evaluation (C
Biotech & Life Sciences in China Update: NMPA Reduces Drug Review Timelines to 120 Days — Key Takeaways
NMPA Reduces Drug Review Timelines to 120 Days — What This Means for Biotech in China In a landmark policy shift effective January 2025, China’s 国家药品监
China’s Revised Human Genetic Resource Regulations Review: What Foreign Biotech Companies Need to Know
China's Revised Human Genetic Resource Regulations Review: What Foreign Biotech Companies Need to Know China's revised 人类遗传资源管理条例 (Human Genetic Resou
NMPA’s New Clinical Trial Exemption Policy for Low-Risk Devices Review: Impact on Medical Device Registration in China
NMPA's New Clinical Trial Exemption Policy for Low-Risk Devices: Impact on Medical Device Registration in China China's 国家药品监督管理局 (National Medical Pr
SIAC vs CIETAC: Which Arbitration Body for China Commercial Disputes?
SIAC vs CIETAC: Which Arbitration Body for China Commercial Disputes? body { font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif; line-height